The agreement is notable in that it contains an option provision for the exclusive license of the Company’s SMARTICLES platform in a specific gene editing field. This represents the first time that the Company’s SMARTICLES technology has been evaluated in connection with gene editing. Further terms of the Agreement were not disclosed.
“SMARTICLES continues to be the most widely licensed delivery technology in the nucleic acid therapeutics sector,” stated J. Michael French, president and CEO of Marina Biotech. “We are now beginning to see expansion in other therapeutic areas such as gene editing. We hope that the unique properties of SMARTICLES opens novel therapeutic opportunities for patients with unmet needs.”